View Financial HealthSynthaverse 배당 및 자사주 매입배당 기준 점검 0/6Synthaverse 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-10.5%자사주 매입 수익률총 주주 수익률-10.5%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jun 04Synthaverse S.A., Annual General Meeting, Jun 29, 2026Synthaverse S.A., Annual General Meeting, Jun 29, 2026, at 12:00 Central European Standard Time.New Risk • Mar 30New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. High level of non-cash earnings (36% accrual ratio). Minor Risk Market cap is less than US$100m (zł254.8m market cap, or US$68.5m).New Risk • Oct 13New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 36% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). High level of non-cash earnings (36% accrual ratio). Minor Risk Market cap is less than US$100m (zł297.6m market cap, or US$80.9m).Reported Earnings • Oct 06Second quarter 2025 earnings released: zł0.059 loss per share (vs zł0.02 profit in 2Q 2024)Second quarter 2025 results: zł0.059 loss per share (down from zł0.02 profit in 2Q 2024). Revenue: zł6.29m (down 59% from 2Q 2024). Net loss: zł4.77m (down 437% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.New Risk • Sep 22New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 36% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). High level of non-cash earnings (36% accrual ratio). Minor Risk Market cap is less than US$100m (zł306.4m market cap, or US$84.5m).공시 • Aug 26Synthaverse S.A. to Report First Half, 2025 Results on Sep 30, 2025Synthaverse S.A. announced that they will report first half, 2025 results on Sep 30, 2025분석 기사 • May 20Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 26% But Growth Is LackingSynthaverse S.A. ( WSE:SVE ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...분석 기사 • Nov 28Synthaverse (WSE:SVE) Posted Healthy Earnings But There Are Some Other Factors To Be Aware OfSynthaverse S.A.'s ( WSE:SVE ) robust earnings report didn't manage to move the market for its stock. Our analysis...Reported Earnings • Nov 21Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: zł13.4m (up 65% from 3Q 2023). Net loss: zł444.0k (loss narrowed 82% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 14% per year whereas the company’s share price has fallen by 12% per year.Reported Earnings • Sep 26Second quarter 2024 earnings released: EPS: zł0.011 (vs zł0.037 in 2Q 2023)Second quarter 2024 results: EPS: zł0.011 (down from zł0.037 in 2Q 2023). Revenue: zł15.2m (down 17% from 2Q 2023). Net income: zł1.42m (down 45% from 2Q 2023). Profit margin: 9.3% (down from 14% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings.공시 • May 31Synthaverse S.A., Annual General Meeting, Jun 25, 2024Synthaverse S.A., Annual General Meeting, Jun 25, 2024.Reported Earnings • May 23First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: zł13.9m (up 16% from 1Q 2023). Net loss: zł394.0k (down 153% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.분석 기사 • Apr 20Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 32% But Growth Is LackingSynthaverse S.A. ( WSE:SVE ) shareholders would be excited to see that the share price has had a great month, posting a...Valuation Update With 7 Day Price Move • Apr 19Investor sentiment improves as stock rises 15%After last week's 15% share price gain to zł5.07, the stock trades at a trailing P/E ratio of 75.1x. Average trailing P/E is 32x in the Biotechs industry in Europe. Total loss to shareholders of 55% over the past three years.분석 기사 • Apr 18Why Synthaverse's (WSE:SVE) Soft Earnings Are Just The Beginning Of Its ProblemsThe market shrugged off Synthaverse S.A.'s ( WSE:SVE ) weak earnings report. Despite the market responding positively...Reported Earnings • Apr 11Full year 2023 earnings released: EPS: zł0.07 (vs zł0.093 in FY 2022)Full year 2023 results: EPS: zł0.07 (down from zł0.093 in FY 2022). Revenue: zł58.6m (up 16% from FY 2022). Net income: zł4.76m (down 22% from FY 2022). Profit margin: 8.1% (down from 12% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.공시 • Feb 02+ 3 more updatesSynthaverse S.A. to Report Q3, 2024 Results on Nov 20, 2024Synthaverse S.A. announced that they will report Q3, 2024 results on Nov 20, 2024Reported Earnings • Nov 26Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: zł8.10m (down 40% from 3Q 2022). Net loss: zł2.42m (down 257% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.Reported Earnings • Sep 21Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: zł18.4m (up 31% from 2Q 2022). Net income: zł2.57m (down 6.1% from 2Q 2022). Profit margin: 14% (down from 20% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.공시 • May 27BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., Annual General Meeting, Jun 22, 2023BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., Annual General Meeting, Jun 22, 2023, at 11:00 Central European Standard Time.Reported Earnings • Apr 21Full year 2022 earnings releasedFull year 2022 results: Revenue: zł50.4m (up 22% from FY 2021). Net income: zł6.08m (up 43% from FY 2021). Profit margin: 12% (up from 10% in FY 2021). The increase in margin was driven by higher revenue.공시 • Feb 03+ 2 more updatesBIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. to Report Q3, 2023 Results on Nov 22, 2023BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that they will report Q3, 2023 results on Nov 22, 2023Valuation Update With 7 Day Price Move • Dec 01Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to zł5.70, the stock trades at a trailing P/E ratio of 56.6x. Average trailing P/E is 49x in the Biotechs industry in Poland. Total returns to shareholders of 487% over the past three years.Reported Earnings • Nov 09Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: zł13.4m (up 105% from 3Q 2021). Net income: zł1.54m (up zł2.11m from 3Q 2021). Profit margin: 11% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 99% per year whereas the company’s share price has increased by 96% per year.분석 기사 • Oct 14BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Seems To Use Debt Quite SensiblySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • Sep 09Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: zł14.0m (down 3.1% from 2Q 2021). Net income: zł2.73m (down 7.6% from 2Q 2021). Profit margin: 20% (in line with 2Q 2021).Valuation Update With 7 Day Price Move • Jul 20Investor sentiment improved over the past weekAfter last week's 36% share price gain to zł4.68, the stock trades at a trailing P/E ratio of 65.3x. Average trailing P/E is 26x in the Biotechs industry in Poland. Total returns to shareholders of 374% over the past three years.Valuation Update With 7 Day Price Move • Jul 04Investor sentiment improved over the past weekAfter last week's 15% share price gain to zł3.64, the stock trades at a trailing P/E ratio of 50.8x. Average trailing P/E is 25x in the Biotechs industry in Poland. Total returns to shareholders of 268% over the past three years.Reported Earnings • May 29First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: zł8.62m (up 55% from 1Q 2021). Net loss: zł758.0k (loss narrowed 36% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 130% per year but the company’s share price has only increased by 62% per year, which means it is significantly lagging earnings growth.Reported Earnings • Apr 17Full year 2021 earnings released: EPS: zł0.067 (vs zł0.071 in FY 2020)Full year 2021 results: EPS: zł0.067 (down from zł0.071 in FY 2020). Revenue: zł41.2m (up 2.5% from FY 2020). Net income: zł4.25m (down 4.3% from FY 2020). Profit margin: 10% (in line with FY 2020). Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has only increased by 67% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improved over the past weekAfter last week's 27% share price gain to zł3.58, the stock trades at a trailing P/E ratio of 48.5x. Average trailing P/E is 28x in the Biotechs industry in Poland. Total returns to shareholders of 291% over the past three years.Valuation Update With 7 Day Price Move • Feb 24Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to zł3.09, the stock trades at a trailing P/E ratio of 41.8x. Average trailing P/E is 33x in the Biotechs industry in Poland. Total returns to shareholders of 268% over the past three years.Valuation Update With 7 Day Price Move • Jan 25Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to zł4.15, the stock trades at a trailing P/E ratio of 56.2x. Average trailing P/E is 48x in the Biotechs industry in Poland. Total returns to shareholders of 342% over the past three years.Valuation Update With 7 Day Price Move • Dec 27Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to zł3.75, the stock trades at a trailing P/E ratio of 50.8x. Average trailing P/E is 49x in the Biotechs industry in Poland. Total returns to shareholders of 257% over the past three years.Valuation Update With 7 Day Price Move • Nov 30Investor sentiment deteriorated over the past weekAfter last week's 30% share price decline to zł4.91, the stock trades at a trailing P/E ratio of 66.5x. Average trailing P/E is 52x in the Biotechs industry in Poland. Total returns to shareholders of 350% over the past three years.분석 기사 • Nov 29More Unpleasant Surprises Could Be In Store For BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Shares After Tumbling 48%BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. ( WSE:BML ) shareholders that were waiting for something to happen...분석 기사 • Nov 16We Think You Should Be Aware Of Some Concerning Factors In BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's (WSE:BML) EarningsBIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s ( WSE:BML ) robust recent earnings didn't do much to move the...Reported Earnings • Nov 11Third quarter 2021 earnings releasedThe company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: zł6.55m (down 21% from 3Q 2020). Net loss: zł577.0k (down zł671.0k from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has increased by 97% per year, which means it is tracking significantly ahead of earnings growth.분석 기사 • May 02Does BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Deserve A Spot On Your Watchlist?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Is New 90 Day High Low • Mar 10New 90-day high: zł12.15The company is up 19% from its price of zł10.25 on 10 December 2020. The Polish market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 1.0% over the same period.분석 기사 • Mar 08Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Jan 29What Percentage Of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) Shares Do Insiders Own?Every investor in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. ( WSE:BML ) should be aware of the most powerful...분석 기사 • Jan 03Should Weakness in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?With its stock down 49% over the past three months, it is easy to disregard BIOMED-LUBLIN Wytwórnia Surowic i...Is New 90 Day High Low • Dec 09New 90-day low: zł10.80The company is down 14% from its price of zł12.55 on 10 September 2020. The Polish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period.분석 기사 • Dec 07BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Takes On Some Risk With Its Use Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Reported Earnings • Nov 13Third quarter 2020 earnings released: EPS zł0.001The company reported a soft third quarter result with weaker earnings and profit margins, although revenues were improved. Third quarter 2020 results: Revenue: zł8.33m (up 4.3% from 3Q 2019). Net income: zł94.0k (down 73% from 3Q 2019). Profit margin: 1.1% (down from 4.4% in 3Q 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 131% per year, which means it is tracking significantly ahead of earnings growth.공시 • Jul 08BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced a financing transactionBIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) announced private placement of 6,000,000 series R shares on July 7, 2020. The company will issue shares of par value of PLN 0.1 per share without preemptive rights. The transaction has been resolved by the management of the company.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 SVE 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: SVE 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Synthaverse 배당 수익률 vs 시장SVE의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (SVE)n/a시장 하위 25% (PL)2.8%시장 상위 25% (PL)7.1%업계 평균 (Biotechs)2.4%분석가 예측 (SVE) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 SVE 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 SVE 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 SVE 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: SVE 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YPL 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/19 02:15종가2026/06/19 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Synthaverse S.A.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Jun 04Synthaverse S.A., Annual General Meeting, Jun 29, 2026Synthaverse S.A., Annual General Meeting, Jun 29, 2026, at 12:00 Central European Standard Time.
New Risk • Mar 30New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. High level of non-cash earnings (36% accrual ratio). Minor Risk Market cap is less than US$100m (zł254.8m market cap, or US$68.5m).
New Risk • Oct 13New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 36% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). High level of non-cash earnings (36% accrual ratio). Minor Risk Market cap is less than US$100m (zł297.6m market cap, or US$80.9m).
Reported Earnings • Oct 06Second quarter 2025 earnings released: zł0.059 loss per share (vs zł0.02 profit in 2Q 2024)Second quarter 2025 results: zł0.059 loss per share (down from zł0.02 profit in 2Q 2024). Revenue: zł6.29m (down 59% from 2Q 2024). Net loss: zł4.77m (down 437% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
New Risk • Sep 22New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 36% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). High level of non-cash earnings (36% accrual ratio). Minor Risk Market cap is less than US$100m (zł306.4m market cap, or US$84.5m).
공시 • Aug 26Synthaverse S.A. to Report First Half, 2025 Results on Sep 30, 2025Synthaverse S.A. announced that they will report first half, 2025 results on Sep 30, 2025
분석 기사 • May 20Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 26% But Growth Is LackingSynthaverse S.A. ( WSE:SVE ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...
분석 기사 • Nov 28Synthaverse (WSE:SVE) Posted Healthy Earnings But There Are Some Other Factors To Be Aware OfSynthaverse S.A.'s ( WSE:SVE ) robust earnings report didn't manage to move the market for its stock. Our analysis...
Reported Earnings • Nov 21Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: zł13.4m (up 65% from 3Q 2023). Net loss: zł444.0k (loss narrowed 82% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 14% per year whereas the company’s share price has fallen by 12% per year.
Reported Earnings • Sep 26Second quarter 2024 earnings released: EPS: zł0.011 (vs zł0.037 in 2Q 2023)Second quarter 2024 results: EPS: zł0.011 (down from zł0.037 in 2Q 2023). Revenue: zł15.2m (down 17% from 2Q 2023). Net income: zł1.42m (down 45% from 2Q 2023). Profit margin: 9.3% (down from 14% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings.
공시 • May 31Synthaverse S.A., Annual General Meeting, Jun 25, 2024Synthaverse S.A., Annual General Meeting, Jun 25, 2024.
Reported Earnings • May 23First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: zł13.9m (up 16% from 1Q 2023). Net loss: zł394.0k (down 153% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
분석 기사 • Apr 20Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 32% But Growth Is LackingSynthaverse S.A. ( WSE:SVE ) shareholders would be excited to see that the share price has had a great month, posting a...
Valuation Update With 7 Day Price Move • Apr 19Investor sentiment improves as stock rises 15%After last week's 15% share price gain to zł5.07, the stock trades at a trailing P/E ratio of 75.1x. Average trailing P/E is 32x in the Biotechs industry in Europe. Total loss to shareholders of 55% over the past three years.
분석 기사 • Apr 18Why Synthaverse's (WSE:SVE) Soft Earnings Are Just The Beginning Of Its ProblemsThe market shrugged off Synthaverse S.A.'s ( WSE:SVE ) weak earnings report. Despite the market responding positively...
Reported Earnings • Apr 11Full year 2023 earnings released: EPS: zł0.07 (vs zł0.093 in FY 2022)Full year 2023 results: EPS: zł0.07 (down from zł0.093 in FY 2022). Revenue: zł58.6m (up 16% from FY 2022). Net income: zł4.76m (down 22% from FY 2022). Profit margin: 8.1% (down from 12% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.
공시 • Feb 02+ 3 more updatesSynthaverse S.A. to Report Q3, 2024 Results on Nov 20, 2024Synthaverse S.A. announced that they will report Q3, 2024 results on Nov 20, 2024
Reported Earnings • Nov 26Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: zł8.10m (down 40% from 3Q 2022). Net loss: zł2.42m (down 257% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
Reported Earnings • Sep 21Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: zł18.4m (up 31% from 2Q 2022). Net income: zł2.57m (down 6.1% from 2Q 2022). Profit margin: 14% (down from 20% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
공시 • May 27BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., Annual General Meeting, Jun 22, 2023BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., Annual General Meeting, Jun 22, 2023, at 11:00 Central European Standard Time.
Reported Earnings • Apr 21Full year 2022 earnings releasedFull year 2022 results: Revenue: zł50.4m (up 22% from FY 2021). Net income: zł6.08m (up 43% from FY 2021). Profit margin: 12% (up from 10% in FY 2021). The increase in margin was driven by higher revenue.
공시 • Feb 03+ 2 more updatesBIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. to Report Q3, 2023 Results on Nov 22, 2023BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that they will report Q3, 2023 results on Nov 22, 2023
Valuation Update With 7 Day Price Move • Dec 01Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to zł5.70, the stock trades at a trailing P/E ratio of 56.6x. Average trailing P/E is 49x in the Biotechs industry in Poland. Total returns to shareholders of 487% over the past three years.
Reported Earnings • Nov 09Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: zł13.4m (up 105% from 3Q 2021). Net income: zł1.54m (up zł2.11m from 3Q 2021). Profit margin: 11% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 99% per year whereas the company’s share price has increased by 96% per year.
분석 기사 • Oct 14BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Seems To Use Debt Quite SensiblySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • Sep 09Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: zł14.0m (down 3.1% from 2Q 2021). Net income: zł2.73m (down 7.6% from 2Q 2021). Profit margin: 20% (in line with 2Q 2021).
Valuation Update With 7 Day Price Move • Jul 20Investor sentiment improved over the past weekAfter last week's 36% share price gain to zł4.68, the stock trades at a trailing P/E ratio of 65.3x. Average trailing P/E is 26x in the Biotechs industry in Poland. Total returns to shareholders of 374% over the past three years.
Valuation Update With 7 Day Price Move • Jul 04Investor sentiment improved over the past weekAfter last week's 15% share price gain to zł3.64, the stock trades at a trailing P/E ratio of 50.8x. Average trailing P/E is 25x in the Biotechs industry in Poland. Total returns to shareholders of 268% over the past three years.
Reported Earnings • May 29First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: zł8.62m (up 55% from 1Q 2021). Net loss: zł758.0k (loss narrowed 36% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 130% per year but the company’s share price has only increased by 62% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Apr 17Full year 2021 earnings released: EPS: zł0.067 (vs zł0.071 in FY 2020)Full year 2021 results: EPS: zł0.067 (down from zł0.071 in FY 2020). Revenue: zł41.2m (up 2.5% from FY 2020). Net income: zł4.25m (down 4.3% from FY 2020). Profit margin: 10% (in line with FY 2020). Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has only increased by 67% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improved over the past weekAfter last week's 27% share price gain to zł3.58, the stock trades at a trailing P/E ratio of 48.5x. Average trailing P/E is 28x in the Biotechs industry in Poland. Total returns to shareholders of 291% over the past three years.
Valuation Update With 7 Day Price Move • Feb 24Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to zł3.09, the stock trades at a trailing P/E ratio of 41.8x. Average trailing P/E is 33x in the Biotechs industry in Poland. Total returns to shareholders of 268% over the past three years.
Valuation Update With 7 Day Price Move • Jan 25Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to zł4.15, the stock trades at a trailing P/E ratio of 56.2x. Average trailing P/E is 48x in the Biotechs industry in Poland. Total returns to shareholders of 342% over the past three years.
Valuation Update With 7 Day Price Move • Dec 27Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to zł3.75, the stock trades at a trailing P/E ratio of 50.8x. Average trailing P/E is 49x in the Biotechs industry in Poland. Total returns to shareholders of 257% over the past three years.
Valuation Update With 7 Day Price Move • Nov 30Investor sentiment deteriorated over the past weekAfter last week's 30% share price decline to zł4.91, the stock trades at a trailing P/E ratio of 66.5x. Average trailing P/E is 52x in the Biotechs industry in Poland. Total returns to shareholders of 350% over the past three years.
분석 기사 • Nov 29More Unpleasant Surprises Could Be In Store For BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Shares After Tumbling 48%BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. ( WSE:BML ) shareholders that were waiting for something to happen...
분석 기사 • Nov 16We Think You Should Be Aware Of Some Concerning Factors In BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's (WSE:BML) EarningsBIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s ( WSE:BML ) robust recent earnings didn't do much to move the...
Reported Earnings • Nov 11Third quarter 2021 earnings releasedThe company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: zł6.55m (down 21% from 3Q 2020). Net loss: zł577.0k (down zł671.0k from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has increased by 97% per year, which means it is tracking significantly ahead of earnings growth.
분석 기사 • May 02Does BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Deserve A Spot On Your Watchlist?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Is New 90 Day High Low • Mar 10New 90-day high: zł12.15The company is up 19% from its price of zł10.25 on 10 December 2020. The Polish market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 1.0% over the same period.
분석 기사 • Mar 08Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
분석 기사 • Jan 29What Percentage Of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) Shares Do Insiders Own?Every investor in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. ( WSE:BML ) should be aware of the most powerful...
분석 기사 • Jan 03Should Weakness in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?With its stock down 49% over the past three months, it is easy to disregard BIOMED-LUBLIN Wytwórnia Surowic i...
Is New 90 Day High Low • Dec 09New 90-day low: zł10.80The company is down 14% from its price of zł12.55 on 10 September 2020. The Polish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period.
분석 기사 • Dec 07BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Takes On Some Risk With Its Use Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Reported Earnings • Nov 13Third quarter 2020 earnings released: EPS zł0.001The company reported a soft third quarter result with weaker earnings and profit margins, although revenues were improved. Third quarter 2020 results: Revenue: zł8.33m (up 4.3% from 3Q 2019). Net income: zł94.0k (down 73% from 3Q 2019). Profit margin: 1.1% (down from 4.4% in 3Q 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 131% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Jul 08BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced a financing transactionBIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) announced private placement of 6,000,000 series R shares on July 7, 2020. The company will issue shares of par value of PLN 0.1 per share without preemptive rights. The transaction has been resolved by the management of the company.